Skip to main content
Premium Trial:

Request an Annual Quote

R&D Surge Widens Illumina s Q4 Net Loss; Revenue Inches Ahead

NEW YORK, Feb. 1 - Illumina on Friday said that a significant increase in R&D spending caused it to post widened net losses in the fourth quarter of 2001.

 

Losses in the period ended Dec. 31 were $8.2 million, or $0.27 per share, compared with $4.6 million, or $0.16 per share in the year-ago quarter, the company said.

 

Although revenue in the period increased to $761,000 from $485,000 year over year, R&D spending ballooned to $6.1 million from $3.8 million one year ago.

 

Illumina, based in San Diego, said it had roughly $94 million in the bank at the end of 2001.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.